The Priority Review

Clinical trials Brief

Braveheart Bio registers Phase 3 trial of BHB-1893 in non-obstructive hypertrophic cardiomyopathy

The study plans to enroll an estimated 600 adults with symptomatic non-obstructive hypertrophic cardiomyopathy, beginning in December 2026 and aiming for primary completion in December 2029. Its main purpose is to find out whether BHB-1893 works better than placebo in adults with non-obstructive hypertrophic cardiomyopathy.

Primary source

ClinicalTrials.gov registry record, November 18, 2026

BHB-1893 vs. Placebo for Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Read the source: BHB-1893 vs. Placebo for Symptomatic Non-obstructive Hypertrophic Cardiomyopathy clinicaltrials.gov

Machine-summarized from the source above; not independently reported. How we use automation